Shenzhen Fushan Biotech

Shenzhen Fushan Biotech is a clinical-stage biopharmaceutical company based in Shenzhen, China, specializing in the discovery and development of innovative small molecule therapeutics. The company primarily focuses on metabolic diseases, including obesity, type 2 diabetes, and non-alcoholic steatohepatitis (NASH), as well as inflammatory conditions. Its lead programs include multi-receptor agonists and selective hormone receptor modulators designed to provide improved efficacy and safety profiles over existing injectable treatments. Fushan Biotech leverages a robust internal R&D platform to advance its pipeline from discovery through clinical validation, aiming to address significant unmet medical needs in the global metabolic health market.